Over the last decade there has been a considerable effort directed toward reformulating the standard approach taken to preclinically model stroke and stroke recovery. The principal objective of this undertaking has been to improve the success with which preclinical findings can be translated. Although several advancements have already been introduced, one potentially critical feature that appears to have been overlooked is psychological stress. Stroke is well recognized to produce high levels of stress in patients, and ongoing exposure to stress is recognized to deleteriously interfere with recovery. The presence of high levels of stress (distress) in stroke patients is also relevant because nearly all clinically deployed neurorestorative interventions occur against this background. Somewhat perplexingly, however, we could find no preclinical stroke studies concerned with investigating the efficacy of putative neurorestorative compounds that did so in the presence of stress. The following article will make the case that failure to recognize or compensate for the effects of ongoing stress in standard preclinical experimental models of recovery is likely to result in overestimation of the effectiveness of pharmacological or behavioral neurorestorative interventions.
INTRODUCTION
Stroke is a major cause of death and long-term disability globally, and represents a major claim on health-care budgets.
1 Although the precise financial burden imposed by stroke is difficult to quantify, the first-year costs of first-ever strokes have been estimated at more than $2 billion per year in Australia, 2 $53.9 billion USD in the United States, 3 and over h38 billion per year across the European Union. 4 Of this total cost, rehabilitative services (inpatient and outpatient) account for the largest component. 2 Despite the considerable effort invested in existing rehabilitative approaches, research has shown that the majority of stroke patients who exhibit significant disability at three months, continue to do so at 12 months. 5 This challenging situation has driven an intense research effort directed toward evaluating promising therapeutic interventions using experimental, animal-based, preclinical models of stroke. Many of the most promising strategies identified using preclinical models have not translated well into clinical practice. In the broadest of terms, this has led to a massive overhaul of the 'standard' model of preclinical research with efforts now directed at redefining testing protocols so that they embrace the complexity and heterogeneity associated with human stroke. One critical element of human recovery, however, that has largely been overlooked in the current discourse relating to the improvement of preclinical models is stress. Although psychological stress has long been recognized to be a major risk factor for stroke, [6] [7] [8] [9] [10] [11] [12] [13] [14] it is also a major, and effectively ubiquitous aspect of stroke recovery. [15] [16] [17] Importantly, because of its ubiquity, almost all clinical interventions directed at improving recovery occur against a background of stress. In contrast, we could find no preclinical studies that have evaluated the efficacy of potential neurorestorative interventions in the presence of stress. There are, however, several preclinical studies that have clearly demonstrated that stress by itself impairs recovery. Given this situation, it would appear that serious consideration should be given to incorporating stress as a standard background feature in preclinical stroke models that are concerned with evaluating the potential effectiveness of interventions designed to enhance recovery from stroke.
STRESS, WHAT ARE WE REALLY TALKING ABOUT?
Mammals, like most other species, have evolved to deal with a raft of unexpected environmental challenges, with some being more mundane and others life threatening. Hans Selye 18 was the first to explicitly equate the word 'stress' with the idea that the body engages in a nonselective response to any serious challenge. Selye 18 further proposed that this response served to reorientate almost all of the animals' cognitive and physiologic systems to deal with the impending challenge. 19 This theoretical foundation has now been elaborated to differentiate between the event that causes a response in the body, and the body's actual response to it. Specifically, it was accepted that a stressor is any stimulus (real or imagined) that substantially threatens the homeostatic balance that exists within the body, whereas by extension, the stress response (often just shortened to stress) is the reaction of the body aimed at reestablishing homeostatic balance. 19, 20 Over recent decades, the conceptualization of stress has been somewhat elaborated, particularly in regard to what the defining features of events are that provoke a stress response. There is now a wide consensus that events be considered stressors only if they are perceived as threatening, and are to some degree uncontrollable and/or unpredictable in nature. 21, 22 The magnitude of the stress response is determined by the intensity of these three combined factors and the biologic history of the organism. 22 Although the definition of a stressor as an event that is perceived to be threatening, unpredictable and/or uncontrollable is useful theoretically, it is also helpful to place this definition within the context of life events. In this regard, for humans, actual or imminent unemployment, poverty, medical illness, and in particular, loss of function due to illness, injury, disability, or discord in intimate personal relationships, are all frequently experienced stressors. 23 In the context of stroke recovery, there are numerous stressors present for most patients even if they are provided with the highest standard of rehabilitative care. For instance, patients frequently experience difficulties with movement, communication, and cognition. 15 Owing to these limitations, which are extremely rapid in their onset poststroke, a recovering patient often has difficulty in performing what previously were routine tasks, such as navigating within the home environment, preparing food, and executing other basic household activities. 24 Further, routine tasks performed outside the home can often, at least initially, require third party assistance, and returning to work in the short or even the medium term is often not feasible. Collectively, each of these stressors can culminate in a significant reduction in the quality of life for affected patients, and give rise to a range of negative emotional states including anxiety, fear, worry, and anger. 15, 24 In clinical research, these negative emotional states are often captured under the umbrella term of distress. 25 
THE PRESENCE OF STRESS DURING RECOVERY FROM STROKE IN CLINICAL TRIALS
Numerous studies have consistently reported the presence of high levels of distress in patients recovering from stroke. 15, 17 Hilari et al 16 found that approximately two-thirds of all stroke patients report high levels of psychological distress early after stroke, and further, that these levels show little reduction across the following 6 months. Apart from a reduction in the patient's perceived quality of life, the presence of high levels of distress is also associated with poorer physical functional outcomes. [26] [27] [28] [29] [30] [31] For instance, West et al 32 found that persistent psychological distress in the first 6 months after stroke predicted a lower Barthel index score, a measurement of competence in performance of activities of daily living, at 1 year.
High levels of stress have also consistently been associated with the emergence of mood-related psychopathology after stroke, especially depression (see Table 1 for further details). It is important to recognize, however, that at the present time, it is not known whether the relationship between distress and moodrelated psychopathology in the context of stroke is causal. What appears to be certain is that the emergence of mood-related psychopathology is not only linked to the presence of stress but also to a confluence of other important mediating factors including the following: the individual's coping skills; 33, 34 personality; 33, 35 social support; 33, 34 and socioeconomic status. 36, 37 Complicating the relationship between stress and mood is a now substantial body of evidence indicating that mood alterations after stroke can be caused by functional destruction or serious disturbance of serotonergic and noradrenergic fiber pathways. 38 Further, several recent studies have indicated that disturbances in inflammatory signaling, that may occur as a result of stroke, can elicit significant changes in mood state 39 in a manner that is apparently independent of any of the aforementioned psychosocial factors. In summary, although the interaction between stress and poorer outcomes poststroke appears to be remarkably consistent, it remains to be specifically determined how stress-signaling pathways interact with other physiologic and psychological alterations induced by stroke to alter mood state.
THE CONSEQUENCES OF STRESS IN THE RECOVERY PHASE AFTER STROKE IN ANIMAL MODELS
A search of the Medline, Cochrane and Psychinfo databases uncovered just nine relevant studies that have examined the effects of stress on stroke recovery in an animal model (see Table 2 ). [40] [41] [42] [43] [44] [45] [46] [47] [48] Although there was little consistency in the absolute time that the animals were exposed to stressful situations, the majority of studies employed a restraint stress paradigm for either 20 minutes daily after induction of stroke or 60 minutes daily commencing seven days before stroke and continuing up to 3 weeks after. Despite this, the majority of studies reported that exposure to persistently stressful situations resulted in significant impairment of recovery; effects that included increased infarct size, and increased motor impairments (see Table 2 ). 42 demonstrated that rats subjected to restraint stress after a photothrombotic stroke in the sensorimotor cortex displayed increased infarct volume and apoptotic cell death in addition to reduced functional recovery compared with rats that underwent the stroke procedure but were not subjected to restraint stress.
SIGNIFICANCE OF STRESS IN PRECLINICAL EXPERIMENTAL MODELS OF STROKE
Perhaps the single greatest frustration faced by those working toward developing improved rehabilitative approaches has been the relatively low rates of successful research translation. This issue relates most specifically to pharmacological interventions that have demonstrated therapeutic potential in the acute phase poststroke during preclinical animal-based evaluation but have faulted during translation. [49] [50] [51] [52] [53] [54] [55] [56] The fact that so many pharmacological interventions have proceeded down this same pathway has resulted in widespread reevaluation of the general approach taken to preclinical modeling. Indeed, there is now a consensus that animal modeling of stroke, and of recovery from stroke needs to be altered to take into account the heterogeneity of human stroke, the variation between human and animal brain structures and functions, and differences in the therapeutic time window between animals and humans, to optimize its ability to preclinically assess interventions. [57] [58] [59] [60] [61] More recent theoretical approaches have highlighted the need to consider factors such as age and gender 55 as well as issues related to other clinical conditions that may be present in human stroke patients such as hypertension, diabetes, heart disease, 62 and use of concomitant medications, 63 in animal stroke models. The Stroke Therapy Academic Industry Roundtable (STAIR) recommendations, developed in 1999 in response to the failure of translation of preclinical findings and updated in 2009, provide guidelines developed to improve the quality of preclinical studies and provide standards for the development of neurorestorative interventions that would ensure that demonstrated preclinical benefits would not be lost in translation to the clinical setting. 63 In addition to improvements to animal-based modeling, these guidelines also include recommendations to ensure good scientific inquiry such as randomization and masked assessment of outcome, and the inclusion of biomarker endpoints common to both the animal model and human patients, to assess modification of the therapeutic target. 63 Clearly, many of the proposed modifications have the potential to vastly improve the precision with which the clinical condition is modeled, and should enhance the generalizability of findings. One issue, however, with these current efforts to improve stroke models, is that they have Stress in experimental models of stroke recovery FR Walker et al not given extensive consideration to the importance that stress has on recovery.
Explicitly recognizing the fact that most individuals affected by stroke experience significant levels of stress throughout the recovery process is critical, as almost all interventions designed to enhance recovery are being evaluated against a background of stress. In stark contrast, we could find no animal-based studies that were focused on evaluating the efficacy of neurorestorative interventions in stroke models that did so against a background of stress. However, a recent study evaluating the effect of chronic mild stress on the effectiveness of Copaxone in mice subjected to a crush injury to the optic nerve, found that stress eliminated the neuroprotective effect of Copaxone observed in non-stressed mice. 64 Owing to the negative effects of stress on recovery, it seems probable that evaluating neurorestorative interventions in its absence is likely to result in significant overestimation of treatment efficacy.
STATISTICAL IMPLICATIONS OF 'BUILDING IN' STRESS TO ANIMAL MODELS OF STROKE RECOVERY
Consideration of the typical effect sizes for deleterious effects of stress gives further indication of the potential problems created by not factoring stress into standard models of recovery. For instance Jin et al 43 , in a representative study, demonstrated that stress significantly increased infarct volume, with an estimated effect size d ¼ 3.67 and impaired motor performance, with an estimated effect size of d ¼ 3.31. In comparison, the effect size for a number of neuroprotective strategies is found to be considerably more modest. For instance, Sphingosine-1-phosphate receptor agonist FTY720 (Fingolimod) has been documented to decrease infract volume with an effect size of d ¼ 1.3. 65 Unfortunately, there is not a sufficiently consistent literature investigating the effects of stress on stroke recovery to undertake a systematic meta-analysis of effect sizes. Nevertheless, on the basis of what has already been shown we could reasonably speculate that many, if not all, of the preclinical interventions so far investigated, if re-evaluated in the presence of ongoing stress, would exhibit considerably more modest effects on recovery (see Figure 1 for a schematic representation of this concept).
RECOVERY PROCESSES THAT ARE POTENTIALLY SENSITIVE TO THE EFFECTS OF STRESS
Although there are numerous studies indicating that infrequent, brief exposures to mildly stressful situations can produce highly enhancing effects on learning, 66, 67 memory, 67-69 executive function, 70, 71 and immunocompetence, [72] [73] [74] exposure to chronic stress exerts almost uniformly negative effects on recovery. This is relatively unsurprising given that chronic stress has been shown to impair a vast number of processes critical to tissue regeneration. Specifically, it has been shown that stress, principally through the actions of cortisol and norepinephrine, impairs angiogenesis; neurogenesis; cytokine expression; immune cell maturation; immune cell trafficking; chemoattractant production; glucose metabolism; neurotransmission; and apoptosis. Each of these impacts has been extensively described in a variety of excellent reviews. [75] [76] [77] [78] [79] [80] [81] [82] Recent research has indicated that the ability of chronic stress to alter tissue regeneration within the central nervous system after stroke may extend far beyond many of the traditionally recognized areas of interference. For instance, in a recent in vivo investigation of the effects of chronic stress on astrocytes, Tynan et al 83 identified that exposure to chronic stress appeared to induce profound structural atrophy of a key cytoskeletal protein within astrocytes known as glial fibrillary acid protein. This finding is of particular interest, as it has previously been shown that genetic disruption of astrocyte-specific cytoskeletal proteins (glial fibrillary acid protein and vimentin) is associated with significantly larger infarct volumes. The full extent of how stress alters glial function, and how these changes could impact upon recovery processes is yet to be fully explored; research findings in this area, however, are rapidly accumulating. 84 
HOW MUCH STRESS IS ALREADY INHERENT IN OUR ANIMAL MODELS OF RECOVERY?
Although the theoretical case for why ongoing stress exposure should be included as a standard feature of animal models is relatively clear, some additional information must first be acquired before any practical adjustments are made. Foremost amongst this information is the extent to which stress is already a part of existing animal models. Certainly, it is the case that stress is not being explicitly built-in to preclinical experimental models of stroke recovery interested in evaluating neurorestorative approaches. This does not mean, however, that the animals are not experiencing some level of stress. Perhaps, the most direct way to obtain this information is by measuring standard indices considered to be influenced by stress, such as the levels of circulating corticosterone, corticosterone-binding globulin, glucocorticoid receptor expression and/or occupancy, adrenal weight, thymus weight, and body weight. Alternatively, with an appropriate experimental design, stress-linked behaviors could also be used to assess levels of stress experienced by the recovering animal. Explicitly quantifying the level of stress present in the recovering animal (and there may be no increase under normal circumstances) will provide clarity about the extent to which ongoing stress exposure needs to be built into existing experimental models so that they more accurately reflect what is seen clinically. Figure 1 . Schematic representation of the potential impact of stress on stroke recovery interventions. The figure illustrates four recovery trajectories: 'normal' recovery in which animals receive neither exposure to stress nor any neurorestorative intervention; 'intervention' in which the animal receives only a neurorestorative intervention; 'stress' in which the animal is exposed to ongoing stress during the recovery period; and 'intervention þ stress' in which the neurorestorative intervention is conducted against a background of ongoing stress. The trajectory for the 'normal' group is based on numerous reports on the recovery of motor function in rodents. 85, 86 Typically, motor performance is significantly degraded by stroke and shows marked improvement across the first 7 to 14 days prior to achieving a relatively stable level, which is substantially below the animals' prestroke level of functioning. The trajectory for the 'intervention' group is illustrative of the level of improvement that has been documented in animals treated with drugs such as g-aminobutyric acid antagonists; 87 Sphingosine-1-phosphate (S1P) receptor agonists; 65 and environmental enrichment. 88 The trajectory for the stress group is indicative of the average level of motor impairment described in Refs 42-48,89. The 'intervention þ stress' group is the only group for which empirical data have not been published. We propose, however, given the broadly negative impact of stress on recovery processes that it is likely to substantially reduce the effectiveness of standard neurorestorative interventions.
CONCLUSION
Within the field, there is now widespread recognition of the fact that existing models of stroke recovery can be improved to more accurately reflect the diverse experiences that are normal to human recovery. The benefits of improving existing models are numerous, but most importantly this endeavor has the potential to allow for higher levels of confidence to be placed in those interventions identified as extremely promising. This in turn creates a stronger platform from which more extensive academic engagement and higher levels of commercial investment can be obtained. Alterations already made to our existing models have steadily improved their realism and accuracy. Clearly, however, there is still room for improvement. Although there are many points of difference between the recovery environments of animals and humans, we suggest that one of the most obvious next steps to improve translational success is to 'build-in' exposure to ongoing stress to directly mimic the clinical reality of the recovery process. Indeed, assuming that stress is low in current models, an argument could be made to add ongoing stress exposure by default to both conventional intervention and control groups, and not include conventional unhandled home cage controls at all. In moving down this pathway, a further practical issue to consider is the likely negative impact that stress will have on therapeutic effect sizes. Accordingly, if this approach is adopted, it is likely that studies evaluating a potential therapeutic against a background of stress, will need to substantially increase sample size to retain the ability to identify differences if they do indeed exist. Undertaking these modifications certainly has the potential to make the execution of recovery models, which are already time consuming, even more challenging, and expensive. In doing so, however, animal models of stroke recovery could take another substantial step toward realistically capturing the processes that determine the trajectory of human recovery from stroke.
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